Ipilimumab Drug Profile

Boxed warning

Severe and fatal immune-mediated adverse reactions (enterocolitis, hepatitis, dermatitis, neuropathy, endocrinopathy)

Clinical alerts

Boxed warning

1 boxed warning

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Monoclonal antibody blocking CTLA-4, enhancing T cell activation

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Advanced Malignant Solid Neoplasm
·Metastatic Malignant Solid Neoplasm
·Unresectable Malignant Solid Neoplasm
·Clinical Stage III Cutaneous Melanoma AJCC v8
·Clinical Stage IV Cutaneous Melanoma AJCC v8

Interactions

No curated interaction pairs are recorded for Ipilimumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Fatigue
Diarrhea
Pruritus
Rash
Colitis

Pharmacokinetics

Published parameters · PMID:23714680

Half-life: 14.7 days
Protein binding: N/A
Clearance: 0.015 L/h; adult melanoma patients
Volume of distribution: 7 L
Renally eliminated: 0%
Model: 1-compartment

Pregnancy & lactation

Not recorded for Ipilimumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.